HC Wainwright Forecasts Stronger Earnings for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Stock analysts at HC Wainwright lifted their FY2025 EPS estimates for Genmab A/S in a note issued to investors on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $1.58 per share for the year, up from their prior estimate of $1.48. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.47 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.51 EPS and Q4 2026 earnings at $0.52 EPS.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

GMAB has been the topic of several other reports. Truist Financial dropped their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $20.79 on Monday. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $30.41. The company has a market cap of $13.76 billion, a PE ratio of 11.95, a P/E/G ratio of 2.65 and a beta of 1.07. The firm’s 50 day moving average price is $20.41 and its 200-day moving average price is $21.00.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. Callan Capital LLC bought a new position in Genmab A/S during the 1st quarter worth about $281,000. Envestnet Asset Management Inc. boosted its position in shares of Genmab A/S by 1.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company’s stock worth $14,417,000 after purchasing an additional 12,545 shares in the last quarter. DAVENPORT & Co LLC grew its stake in Genmab A/S by 21.1% during the 1st quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company’s stock worth $620,000 after buying an additional 5,529 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 20.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company’s stock valued at $4,885,000 after buying an additional 42,361 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Genmab A/S by 169.9% during the first quarter. Blue Trust Inc. now owns 7,413 shares of the company’s stock worth $145,000 after acquiring an additional 4,666 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.